Diet ModificationDTCUNCT02047136
Dietary Treatment for Chronic Urticaria
A study testing Treatment group (on low histamine diet) and Well-balanced diet in people with Diet Modification and Chronic Urticaria, run by Hong Kong Sanatorium & Hospital at 1 site in China.
Trial summary
Histamine is a biologically active component that can be found in many foods and beverages. Intake of excessive histamine from foods or beverages, can trigger symptoms including urticaria. A low histamine diet has been recommended as one of the possible treatments for patients with chronic urticaria. Read more about this study
- Who is it for?
- Ages 8 years and olderHealthy volunteers can take part
- Conditions the study is for
- Diet Modification, Chronic Urticaria
- What is being tested?
- Treatment group (on low histamine diet) and Well-balanced diet
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 1 siteChina
- Study dates
- Sep 2013to Jul 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Urticaria +/- angioedema present for a minimum of 6 weeks;
- Agree to be on anti-histamine prn;
- Age older than 8 years old, with no upper age limit;
- Causes such as parasite infestation, microbial and viral infections, autoimmune disease, or other pathology that could account for the U/A/P should be excluded;
- Skin prick test and/or radioallergosorbent (RAST) test are negative for all food allergens tested, or patient had achieved no symptomatic improvement after strict avoidance of all skin test-positive foods;
Who cannot join
- Pregnant or breast feeding women;
- Patients who is taking central nervous system (CNS) acting agents (including tranquilizers, antidepressants, sedatives, hypnotics or antiepileptics) at any time;
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Can Low Histamine Diet Reduce Symptoms of Patients With Idiopathic Urticaria?
Histamine is a biologically active component that can be found in many foods and beverages. Intake of excessive histamine from foods or beverages, can trigger symptoms including urticaria. A low histamine diet has been recommended as one of the possible treatments for patients with chronic urticaria. There are very few studies to confirm the effectiveness of such diets and, to the investigators' knowledge, none from Asia where high histamine containing meals are often eaten (personal observations). The objective of the present study is to investigate the therapeutic effect of low histamine diet in relieving symptoms in patients with chronic urticaria with or without angioedema, and / or pruritus (U/A/P). The investigators hypothesize that following a low histamine diet for 4 weeks, the symptoms of patients with chronic U/A/P should improve.
Read the detailed description
A double blinded parallel randomized control study over 4 weeks will be conducted to assess the effectiveness of a histamine-restricted diet. Neither the subjects nor the medical investigator will know which diet is being prescribed.
The study will only be conducted after ethical approval has been granted and with informed consent. If it is a child, informed consent will be obtained from a parent. Subject has to pay his/her consultation fee for doctor's and dietitian's consultation and skin prick and/or blood tests at the first visit as normal but there will be no charge for subsequent visits in relation to the trial.
A period of 4 weeks on the low histamine diet has previously been shown to be sufficient to determine whether dietary manipulation will help in the management of the urticaria symptoms.
Selection Criteria and sample size calculation 78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed. Subjects in both groups are also instructed to have adequate water intake during the study period. Both groups are asked to record food diary and symptoms during the study period. Consent form will state that it is a study to compare the efficacy of both diets. After the study period, subjects in the CG will be able to follow a low histamine diet if this is proven to be beneficial, so everyone will have the potential to benefit from the low histamine diet and vice versa for the TG subjects.
Low Histamine Diet Histamine is present in almost all foods in small quantities. Its presence increases with maturation of the food. High quantities of histamine are found mainly in products of microbial fermentation, such as aged cheese, sauerkraut, wine, and processed meat. Some oriental foods with high histamine content are also included.The current Low Histamine Diet sheet of Hong Kong Sanatorium \& Hospital will be used (Appendix I).
Evaluation of Symptoms When a subject comes for the first consultation (randomization week), he/she will be given a 4-point scale questionnaire (see Appendix II) to evaluate his/her own symptoms (pruritus severity and number of wheals). This will be completed once every evening for a week prior to the 4-week treatment period. The pruritus severity score and the number of wheals during this run in week will be averaged and used as the mean baseline score. The summation of mean pruritus score (MPS) and the mean number of wheals (MNW) will be the mean total symptoms score (MTSS) for the baseline period. Medical investigator will also evaluate the subject's global symptoms severity (GSS) at the first consultation (randomization week) and second consultation (at the end of week 4).
MPS and GSS is scored as 0 = none; 1 = mild (present but not disturbing); 2 = moderate (disturbing but not hampering day time activities and/or sleep); and 3 = severe/intense (disturbing and hampering day time activities and/or sleep). Number of wheals are scored as 0 = none; 1 = mild (less than 20 wheals per 24 hours); 2 = moderate (21-50 wheals); and 3 = severe (more than 50 wheals).
After the first consultation with the medical investigator, a skin prick test and/or blood tests for specific immunoglobulin E (IgE) to eight major food allergens will be tested, namely cow's milk, egg, peanut, treenuts, wheat, soya, seafood, shellfish. Subject will consult a dietitian for either a well-balanced diet (CG) or low histamine diet (TG) and he/she is asked only to start the diet one week after the first consultation. The subject will be asked to fax or email his/her completed questionnaire and food diary for checking before he/she starts the diet. Dietitian will ensure that the questionnaire and the food diary are completed correctly by the subject. Dietitian will then phone the subject not only to remind him/her to start on the diet but also to make sure that the subject corrects any errors in completing the questionnaire and food diary. If the diary during the run in period is done very poorly it may have to be repeated before the formal diet begins. Dietitian will conduct subsequent weekly phone follow up with each subject. Each subject will be reminded to complete their questionnaires and food diaries every evening.
For each symptom the scores for each week will be averaged. The sum of MPS and MNW is the mean total symptoms score (MTSS) and this will also be averaged for each week period.
Evaluation of compliance of low histamine diet
Each subject will complete a food diary, in addition to the symptom score chart, where he/she will record his/her dietary intake for each snack and meal during the 4-week study period. The food diary will be evaluated by the Allergy Centre dietitians for adherence to the diet. Diet compliance score (DCS) is scored as 0 = not comply at all; 1 = poor diet compliance (intake of 2 or more high histamine foods daily); 2 = good compliance (intake of 1 or less high histamine food daily); 3 = excellent diet compliance (intake of 3 or less high histamine food per week).
Randomization and blinding After provision of informed consent, subjects will be allocated by a table of random numbers to either the TG or CG. The number sequence will be generated by the computer list prepared by dietitians. Neither the subjects nor the medical investigator will know which diet is being prescribed to which subject.
Power calculations and statistical analysis
Sample size was determined based on a previous drug study13 as there is insufficient data on low histamine diets. To detect a clinically significant mean difference of at least 1 point between the active and control groups on the 4 point scale with 80% power at p< 0.05 requires 35 subjects in each trial arm. Allowing for a 10% drop out rate, the total sample should be 78 individuals.
Statistical analyses will be performed by hospital statisticians using SPSS version 18.0.0 (2009). The primary outcomes will be the change in Mean Total Symptoms Score (MTSS) from baseline between groups. Secondary outcome measures will include assessment of (1) the change in MPS between groups; (2) the change in MNW between groups. (3) the change in GSS by medical investigator between groups; (4) the comparison of area under the curve (AUC for the trend) for MTSS, MPS, MNW, GSS and DCS between the groups during the 4-week period; and (5) the comparison of total dose of anti-histamine used by each group compared to baseline within the study period. All data will be analyzed using paired student's t-test.
- Conditions
- Diet Modification, Chronic Urticaria
- Being tested
- Treatment group (on low histamine diet), Well-balanced diet
- Medical subject headings
- Chronic Urticaria
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Treatment group (on low histamine diet)Other
78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
Well-balanced dietOther
Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
| Study group | Role | What they receive |
|---|---|---|
| Treatment group (on low histamine diet) | Experimental | 78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed. Receives: Other: Treatment group (on low histamine diet) |
| Well-balanced diet | Active comparator | Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed. Receives: Other: Well-balanced diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
The change in Mean Total Symptoms Score (MTSS) from baseline between groups
When a subject comes for the first consultation (randomization week), he/she will be given a 4-point scale questionnaire (see Appendix II) to evaluate his/her own symptoms (pruritus severity and number of wheals). This will be completed once every evening for a week prior to the 4-week treatment period. The pruritus severity score and the number of wheals during this run in week will be averaged and used as the mean baseline score. The summation of mean pruritus score (MPS) and the mean number of wheals (MNW) will be the mean total symptoms score (MTSS) for the baseline period. Then comparison between the change in Mean Total Symptoms Score (MTSS) from baseline between treatment group and control group.
Measured: 4 weeks
Secondary outcomes (4)
the change in mean pruritus score (MPS) between treatment group and control group
When a subject comes for the first consultation (randomization week), he/she will be given a 4-point scale questionnaire (see Appendix II) to evaluate his/her own symptoms (pruritus severity and number of wheals). This will be completed once every evening for a week prior to the 4-week treatment period. The pruritus severity score and the number of wheals during this run in week will be averaged and used as the mean baseline score. The summation of mean pruritus score (MPS) and the mean number of wheals (MNW) will be the mean total symptoms score (MTSS) for the baseline period.
Measured: 4 week
the change in mean number of wheals (MNW) between groups
When a subject comes for the first consultation (randomization week), he/she will be given a 4-point scale questionnaire to evaluate his/her own symptoms (pruritus severity and number of wheals). This will be completed once every evening for a week prior to the 4-week treatment period. The pruritus severity score and the number of wheals during this run in week will be averaged and used as the mean baseline score. The summation of mean pruritus score (MPS) and the mean number of wheals (MNW) will be the mean total symptoms score (MTSS) for the baseline period.
Measured: 4 week
the change in global symptoms severity (GSS) by medical investigator between groups
Medical investigator will also evaluate the subject's global symptoms severity (GSS) at the first consultation (randomization week) and second consultation (at the end of week 4).
Measured: 5 weeks
the comparison of area under the curve (AUC for the trend) for MTSS, MPS, MNW, GSS and DCS between the groups during the 4-week period
When a subject comes for the first consultation (randomization week), he/she will be given a 4-point scale questionnaire to evaluate his/her own symptoms (pruritus severity and number of wheals). This will be completed once every evening for a week prior to the 4-week treatment period. The pruritus severity score and the number of wheals during this run in week will be averaged and used as the mean baseline score. The summation of mean pruritus score (MPS) and the mean number of wheals (MNW) will be the mean total symptoms score (MTSS) for the baseline period. Medical investigator will also evaluate the subject's global symptoms severity (GSS) at the first consultation (randomization week) and second consultation (at the end of week 4).
MPS and GSS is scored as 0 = none; 1 = mild (present but not disturbing); 2 = moderate (disturbing but not hampering day time activities and/or sleep); and 3 = severe/intense (disturbing and hampering day time activities and/or sleep).
Measured: 4 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2014 (estimated)
- Study startSep 2013
- Primary completionDec 2017
- Study completionJul 2018
Why it stopped: Unable to recruit subjects, patients want active treatment instead of placebo.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Diet ModificationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hong Kong Sanatorium & Hospital
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Wai Yan Vivian Lau, Master, Principal investigator, Hong Kong Sanatorium & Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02047136
- Sponsor's protocol ID
- ALC-001
- Acronym
- DTCU
- Status last verified
- Jul 2018
- First submitted
- 24 Jan 2014
- Last updated
- 2 Aug 2018
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007 May;85(5):1185-96. doi: 10.1093/ajcn/85.5.1185.
PubMed 17490952Janice M. Vickerstaff Joneja, Cabrini Carmona-Silva. Outcome of a Histamine-restricted Diet Based on Chart Audit. Journal of Nutritional and Environmental Medicine 11(4): 249-262, 2001.
Study at a glance
From the registry record, last updated by the sponsor on 2 Aug 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Can Low Histamine Diet Reduce Symptoms of Patients With Idiopathic Urticaria?
- ClinicalTrials.gov ID
- NCT02047136
- Acronym / sponsor ID
- DTCU / ALC-001
- Conditions
- Diet Modification, Chronic Urticaria
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Unable to recruit subjects, patients want active treatment instead of placebo.
- Enrolment
- 8 participants (actual)
- Lead sponsor
- Hong Kong Sanatorium & HospitalIndustry (pharma, biotech, devices)
- Study start
- Sep 2013 (actual)
- Primary completion
- Dec 2017 (actual)
- Study completion
- Jul 2018 (actual)
- First posted
- 28 Jan 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Histamine is a biologically active component that can be found in many foods and beverages. Intake of excessive histamine from foods or beverages, can trigger symptoms including urticaria. A low histamine diet has been recommended as one of the possible treatments for patients with chronic urticaria. There are very few studies to confirm the effectiveness of such diets and, to the investigators' knowledge, none from Asia where high histamine containing meals are often eaten (personal observations). The objective of the present study is to investigate the therapeutic effect of low histamine diet in relieving symptoms in patients with chronic urticaria with or without angioedema, and / or pruritus (U/A/P). The investigators hypothesize that following a low histamine diet for 4 weeks, the symptoms of patients with chronic U/A/P should improve.
Detailed description
A double blinded parallel randomized control study over 4 weeks will be conducted to assess the effectiveness of a histamine-restricted diet. Neither the subjects nor the medical investigator will know which diet is being prescribed.
The study will only be conducted after ethical approval has been granted and with informed consent. If it is a child, informed consent will be obtained from a parent. Subject has to pay his/her consultation fee for doctor's and dietitian's consultation and skin prick and/or blood tests at the first visit as normal but there will be no charge for subsequent visits in relation to the trial.
A period of 4 weeks on the low histamine diet has previously been shown to be sufficient to determine whether dietary manipulation will help in the management of the urticaria symptoms.
Selection Criteria and sample size calculation 78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed. Subjects in both groups are also instructed to have adequate water intake during the study period. Both groups are asked to record food diary and symptoms during the study period. Consent form will state that it is a study to compare the efficacy of both diets. After the study period, subjects in the CG will be able to follow a low histamine diet if this is proven to be beneficial, so everyone will have the potential to benefit from the low histamine diet and vice versa for the TG subjects.
Low Histamine Diet Histamine is present in almost all foods in small quantities. Its presence increases with maturation of the food. High quantities of histamine are found mainly in products of microbial fermentation, such as aged cheese, sauerkraut, wine, and processed meat. Some oriental foods with high histamine content are also included.The current Low Histamine Diet sheet of Hong Kong Sanatorium \& Hospital will be used (Appendix I).
Evaluation of Symptoms When a subject comes for the first consultation (randomization week), he/she will be given a 4-point scale questionnaire (see Appendix II) to evaluate his/her own symptoms (pruritus severity and number of wheals). This will be completed once every evening for a week prior to the 4-week treatment period. The pruritus severity score and the number of wheals during this run in week will be averaged and used as the mean baseline score. The summation of mean pruritus score (MPS) and the mean number of wheals (MNW) will be the mean total symptoms score (MTSS) for the baseline period. Medical investigator will also evaluate the subject's global symptoms severity (GSS) at the first consultation (randomization week) and second consultation (at the end of week 4).
MPS and GSS is scored as 0 = none; 1 = mild (present but not disturbing); 2 = moderate (disturbing but not hampering day time activities and/or sleep); and 3 = severe/intense (disturbing and hampering day time activities and/or sleep). Number of wheals are scored as 0 = none; 1 = mild (less than 20 wheals per 24 hours); 2 = moderate (21-50 wheals); and 3 = severe (more than 50 wheals).
After the first consultation with the medical investigator, a skin prick test and/or blood tests for specific immunoglobulin E (IgE) to eight major food allergens will be tested, namely cow's milk, egg, peanut, treenuts, wheat, soya, seafood, shellfish. Subject will consult a dietitian for either a well-balanced diet (CG) or low histamine diet (TG) and he/she is asked only to start the diet one week after the first consultation. The subject will be asked to fax or email his/her completed questionnaire and food diary for checking before he/she starts the diet. Dietitian will ensure that the questionnaire and the food diary are completed correctly by the subject. Dietitian will then phone the subject not only to remind him/her to start on the diet but also to make sure that the subject corrects any errors in completing the questionnaire and food diary. If the diary during the run in period is done very poorly it may have to be repeated before the formal diet begins. Dietitian will conduct subsequent weekly phone follow up with each subject. Each subject will be reminded to complete their questionnaires and food diaries every evening.
For each symptom the scores for each week will be averaged. The sum of MPS and MNW is the mean total symptoms score (MTSS) and this will also be averaged for each week period.
Evaluation of compliance of low histamine diet
Each subject will complete a food diary, in addition to the symptom score chart, where he/she will record his/her dietary intake for each snack and meal during the 4-week study period. The food diary will be evaluated by the Allergy Centre dietitians for adherence to the diet. Diet compliance score (DCS) is scored as 0 = not comply at all; 1 = poor diet compliance (intake of 2 or more high histamine foods daily); 2 = good compliance (intake of 1 or less high histamine food daily); 3 = excellent diet compliance (intake of 3 or less high histamine food per week).
Randomization and blinding After provision of informed consent, subjects will be allocated by a table of random numbers to either the TG or CG. The number sequence will be generated by the computer list prepared by dietitians. Neither the subjects nor the medical investigator will know which diet is being prescribed to which subject.
Power calculations and statistical analysis
Sample size was determined based on a previous drug study13 as there is insufficient data on low histamine diets. To detect a clinically significant mean difference of at least 1 point between the active and control groups on the 4 point scale with 80% power at p< 0.05 requires 35 subjects in each trial arm. Allowing for a 10% drop out rate, the total sample should be 78 individuals.
Statistical analyses will be performed by hospital statisticians using SPSS version 18.0.0 (2009). The primary outcomes will be the change in Mean Total Symptoms Score (MTSS) from baseline between groups. Secondary outcome measures will include assessment of (1) the change in MPS between groups; (2) the change in MNW between groups. (3) the change in GSS by medical investigator between groups; (4) the comparison of area under the curve (AUC for the trend) for MTSS, MPS, MNW, GSS and DCS between the groups during the 4-week period; and (5) the comparison of total dose of anti-histamine used by each group compared to baseline within the study period. All data will be analyzed using paired student's t-test.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment group (on low histamine diet) | Experimental | Other: Treatment group (on low histamine diet)78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed. |
| Well-balanced diet | Active comparator | Other: Well-balanced dietDiet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed. |
Who may qualify
- Ages
- 8 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Urticaria +/- angioedema present for a minimum of 6 weeks;
- Agree to be on anti-histamine prn;
- Age older than 8 years old, with no upper age limit;
- Causes such as parasite infestation, microbial and viral infections, autoimmune disease, or other pathology that could account for the U/A/P should be excluded;
- Skin prick test and/or radioallergosorbent (RAST) test are negative for all food allergens tested, or patient had achieved no symptomatic improvement after strict avoidance of all skin test-positive foods;
Key exclusion criteria (2 listed)
- Pregnant or breast feeding women;
- Patients who is taking central nervous system (CNS) acting agents (including tranquilizers, antidepressants, sedatives, hypnotics or antiepileptics) at any time;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Treatment group (on low histamine diet)78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed. | Other | Treatment group (on low histamine diet) |
| Well-balanced dietDiet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed. | Other | Well-balanced diet |
Primary outcome
The change in Mean Total Symptoms Score (MTSS) from baseline between groups
Time frame: 4 weeks
When a subject comes for the first consultation (randomization week), he/she will be given a 4-point scale questionnaire (see Appendix II) to evaluate his/her own symptoms (pruritus severity and number of wheals). This will be completed once every evening for a week prior to the 4-week treatment period. The pruritus severity score and the number of wheals during this run in week will be averaged and used as the mean baseline score. The summation of mean pruritus score (MPS) and the mean number of wheals (MNW) will be the mean total symptoms score (MTSS) for the baseline period. Then comparison between the change in Mean Total Symptoms Score (MTSS) from baseline between treatment group and control group.
4 secondary outcomes
the change in mean pruritus score (MPS) between treatment group and control group
Time frame: 4 week
the change in mean number of wheals (MNW) between groups
Time frame: 4 week
the change in global symptoms severity (GSS) by medical investigator between groups
Time frame: 5 weeks
the comparison of area under the curve (AUC for the trend) for MTSS, MPS, MNW, GSS and DCS between the groups during the 4-week period
Time frame: 4 week
Results and safety
The study was stopped early (reason given: Unable to recruit subjects, patients want active treatment instead of placebo.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Aug 2018.
- Results publication: PubMed 17490952Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007 May;85(5):1185-96. doi: 10.1093/ajcn/85.5.1185.
- Results publicationJanice M. Vickerstaff Joneja, Cabrini Carmona-Silva. Outcome of a Histamine-restricted Diet Based on Chart Audit. Journal of Nutritional and Environmental Medicine 11(4): 249-262, 2001.
Related trials for Diet Modification
Active, not recruiting
Chrono Nutrition and Insulin Resistance in Diabetes
Diabetes Mellitus, Type 2
Recruiting
SHIFT-TB: Nutrition Intervention and Evaluation
Underweight, Overweight and Obesity
Recruiting
Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change
Overweight, Obesity
Recruiting
Dietary Intervention to Improve Fertility in Women With Endometriosis Undergoing IVF
Endometriosis
Recruiting
Dietary Intervention for Migraine Relief
Migraine
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wai Yan Vivian Lau, Master principal investigator
Hong Kong Sanatorium & Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Treatment group (on low histamine diet) and Well-balanced diet in people with Diet Modification and Chronic Urticaria, run by Hong Kong Sanatorium & Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 2 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Unable to recruit subjects, patients want active treatment instead of placebo.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The change in Mean Total Symptoms Score (MTSS) from baseline between groups (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02047136, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Aug 2018.